MYRIAD GENETICS INC's ticker is MYGN and the CUSIP is 62855J104. A total of 184 filers reported holding MYRIAD GENETICS INC in Q3 2023. The put-call ratio across all filers is 0.05 and the average weighting 0.0%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q1 2018 | $7,331,000 | -9.4% | 248,090 | +5.2% | 0.35% | -12.9% |
| Q4 2017 | $8,096,000 | -27.4% | 235,735 | -23.5% | 0.40% | -38.4% |
| Q3 2017 | $11,146,000 | +29.2% | 308,063 | -7.7% | 0.65% | +13.2% |
| Q2 2017 | $8,625,000 | -12.9% | 333,779 | -35.3% | 0.58% | -9.3% |
| Q1 2017 | $9,906,000 | +47.7% | 515,921 | +28.2% | 0.64% | +26.4% |
| Q4 2016 | $6,709,000 | +21.7% | 402,435 | +50.3% | 0.50% | +23.9% |
| Q3 2016 | $5,511,000 | +99.0% | 267,771 | +195.9% | 0.41% | +72.0% |
| Q2 2016 | $2,770,000 | -87.3% | 90,508 | -84.5% | 0.24% | -87.9% |
| Q1 2016 | $21,867,000 | -22.3% | 584,204 | -10.4% | 1.94% | -26.7% |
| Q4 2015 | $28,153,000 | +0.4% | 652,288 | -12.8% | 2.65% | -4.4% |
| Q3 2015 | $28,030,000 | +6.0% | 747,861 | -3.9% | 2.77% | +34.8% |
| Q2 2015 | $26,439,000 | +40.4% | 777,833 | +46.2% | 2.06% | +35.9% |
| Q1 2015 | $18,830,000 | – | 531,933 | – | 1.51% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Camber Capital Management LP | 5,000,000 | $90,850,000 | 3.94% |
| Altium Capital Management LP | 221,000 | $4,016,000 | 1.61% |
| DISCIPLINED GROWTH INVESTORS INC /MN | 1,900,787 | $34,537,000 | 0.93% |
| Zebra Capital Management LLC | 15,352 | $279,000 | 0.82% |
| PFM Health Sciences, LP | 1,177,250 | $21,391,000 | 0.82% |
| EARNEST PARTNERS LLC | 6,462,138 | $117,417,000 | 0.78% |
| Glenview Capital Management | 1,696,791 | $30,831,000 | 0.77% |
| AIMZ Investment Advisors, LLC | 42,085 | $765,000 | 0.37% |
| Phocas Financial Corp. | 127,949 | $2,325,000 | 0.35% |
| Redhawk Wealth Advisors, Inc. | 34,680 | $630,000 | 0.29% |